Ron Bentsur, Chairman & CEO, 10% Owner at Nuvectis Pharma, Inc. (NVCT), bought 1,080 shares at $11.19 ($12K) on 2023-10-09, disclosed to the SEC on 2023-10-10.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $11.27 | 250 | $3K | 23.3% |
| 2 | $11.19 | 830 | $9K | 76.7% |
| Total | $11.21 avg | 1,080 | $12K | 100% |
| Filing → |
| NVCT | BUY | 2024-12-26 | $21K | — | Filing → |
| NVCT | BUY | 2024-11-18 | $98K | — | Filing → |
| NVCT | BUY | 2024-05-15 | $13K | — | Filing → |